A pancreas-targeting dipeptide bioregulator that may support insulin secretion and glucose metabolism.
A dipeptide (Lys-Glu) bioregulator targeting pancreatic beta cells. Research from the Khavinson group suggests it normalises insulin secretion capacity and glucose tolerance in models of metabolic dysfunction, likely through gene regulatory interactions in beta cell nuclei.
Pancragen is used in Russian bioregulator protocols as part of comprehensive metabolic support, particularly in older patients with declining insulin sensitivity. It represents a tissue-targeted approach to metabolic bioregulation.
The dipeptide structure (Lys-Glu) makes it the simplest peptide in the Khavinson bioregulator family, yet it is proposed to exert meaningful effects on pancreatic gene regulation.